Having the right training strategy is critical to building successful collaborations with integrated customers, including ACOs and IDNs. To be successful, sales teams need to understand the strategic goals of the organization as a whole—not just the needs of providers who use their products. Download CMR Institute’s expert whitepaper to explore your customers’ enterprise-wide requirements and discover potential training gaps these needs are creating.
Payers, providers, and policy makers have become keenly interested in managing the health of specific populations, particularly those with chronic conditions who tend to be high utilizers of care. These payers and providers are designing programs that better coordinate care for high-risk patients in an effort to improve quality and reduce costs.
In the following whitepaper, CMR Institute asked top executives at major ACOs and other healthcare systems for key insights and perspectives to help commercial sales teams and account managers be more successful in this new healthcare marketplace.
In this whitepaper, we offer three organizational structures — pillars on which to build a winning launch. In architecture a pillar holds the weight of the portico or roof above structural elements below. In the same way, these pillars-to-launch support practices that prioritize early planning and operational preparedness.
The Life Sciences industry is enduring close regulatory scrutiny, which is likely to continue to expand in scope. For Life Sciences, compliance regulations and practices such as the Physicians Payment Sunshine Act require extensive documentation related to financial and policies management as well as the data associated with these processes. There is not a one size fits all approach resulting in fragmented processes, and copious systems whose remit is to define and collect valuable data. Discover lessons learned and review solutions to ensuring valuable data collection and quality reporting.
The pharmaceutical industry’s recent, record-breaking mergers and acquisitions activity shows no signs of abating as more companies adopt it as a strategic path to the future. In the face of the skyrocketing R&D costs, dwindling pipelines, and increased pressure to reduce healthcare spending, M&As offer companies an opportunity to streamline operations by scaling back on redundant resources as well as divesting and outsourcing non-core competencies. Outsourcing packaging and dispensing is not new. What is new, however, is the increasingly important role packaging plays in the development and marketing of a drug. Outsourcing to a packaging provider with specialized capabilities can both reduced costs, and also increased sales through product differentiation in a new, highly competitive, patient-centric market.
A 505(b)(2) application is a new drug application that contains full safety and effectiveness reports, but allows at least some of the information required for approval to come from studies not conducted by or for the applicant. This approach can lead to approval in a fraction of the time and cost required by traditional paths. For 505(b)(2) in particular, early assessment and preparation are key to identifying needs and avoiding redundancies to set the path to a profitable product. Pre-investigational new drug (PIND) meetings serve as a prudent step in this process and can guide development strategies that reduce time to market and can all but eliminate the possibility of clinical holds.
The industry's much talked-about patient-centered approach requires more than lip-service and organizational redesigns. In order for the patient to emerge center stage in a commercial approach, it's necessary for manufacturers to shift prioritization's to help the greatest number of patients gain access and remain on treatments. This requires aligning both R&D and marketing efforts with patient needs in order to drive positive outcomes— clinical as well as behavioral. The result is a successful product with far greater commercial value in a crowded and highly competitive market.
This eBook, sponsored by AmerisourceBergen, offers actionable strategies, targeted solutions, and specific directions on how to get there.
Pharmaceutical companies face compliance and reporting requirements of the Physicians Payments Sunshine Act of the Affordable Care Act. Many companies are trying to meet these requirements using highly inefficient tools. There is a better way.
This white paper explores the current landscape of planning trends and challenges in clinical development, and presents solutions and best practices that biopharmaceutical and medical device companies are utilizing to increase planning efficiency.
By understanding the needs and incentives of key stakeholders in the context of the commercial environment, market access can validate the opportunity for potential investors or licenses to maximize commercial success.